VIVUS Inc.Find Ratings Reports
VIVUS INC's gross profit margin for the third quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. VIVUS INC is extremely liquid. Currently, the Quick Ratio is 6.99 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 100.93% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY17||Q3 FY16|
|Net Sales ($mil)||15.19||13.35|
|Net Income ($mil)||-5.99||-9.15|
|Balance Sheet||Q3 FY17||Q3 FY16|
|Cash & Equiv. ($mil)||236.02||283.59|
|Total Assets ($mil)||266.74||313.15|
|Total Debt ($mil)||234.71||238.89|
|Profitability||Q3 FY17||Q3 FY16|
|Gross Profit Margin||77.89||86.47|
|Return on Assets||13.54||-14.51|
|Return on Equity||10176.61||0.0|
|Debt||Q3 FY17||Q3 FY16|
|Share Data||Q3 FY17||Q3 FY16|
|Shares outstanding (mil)||105.86||104.82|
|Div / share||0.0||0.0|
|Book value / share||0.0||-0.36|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||721895.0||688092.0|
SELL. VIVUS INC's P/E ratio indicates a significant discount compared to an average of 105.10 for the Pharmaceuticals industry and a significant discount compared to the S&P 500 average of 25.66. For additional comparison, its price-to-book ratio of 145.45 indicates a significant premium versus the S&P 500 average of 3.28 and a significant premium versus the industry average of 7.60. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. The valuation analysis reveals that, VIVUS INC seems to be trading at a discount to investment alternatives within the industry.
|VVUS 1.41||Peers 105.10||VVUS NM||Peers 17.82|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
VVUS is trading at a significant discount to its peers.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
VVUS's P/CF is negative making the measure meaningless.
|VVUS NM||Peers 14.20||VVUS NM||Peers 0.51|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
VVUS's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
VVUS's negative PEG ratio makes this valuation measure meaningless.
|VVUS 145.45||Peers 7.60||VVUS 177.27||Peers -278.29|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
VVUS is trading at a significant premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
VVUS is expected to have an earnings growth rate that significantly exceeds its peers.
|VVUS 0.38||Peers 25.39||VVUS 133.99||Peers 23.77|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
VVUS is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
VVUS has a sales growth rate that significantly exceeds its peers.